Customer Service:
Mon - Fri: 8:30 am - 6 pm EST


CLSI M100-S24

Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement

This document provides updated tables for the Clinical and Laboratory Standards Institute antimicrobial susceptibility testing standards M02-A11, M07-A9, and M11-A8.New or revised interpretive criteria are available for the following drugs.Revised cefepime disk diffusion and minimal inhibitory concentration (MIC) interpretive criteria along with dosage regimens for using susceptible-dose dependent (SDD) interpretive criteria. New cefazolin interpretive criteria and recommendations for use as a surrogate test for uncomplicated urinary tract infections to predict results for oral cephalosporins. New doripenem disk diffusion and MIC interpretive criteria with dosage regimens on which the breakpoints are basedRevised imipenem and meropenem disk diffusion and MIC interpretive criteria with dosage regimens on which the breakpoints are based. Added: Definition for SDD, An example and explanation for antimicrobial agents having only susceptible interpretive criteria, Information for reporting first- and second-generation cephalosporins and cephamycins for Salmonella spp. and Shigella spp, Updated recommendations for the placement of disks on a 100-mm plate.

Content Provider
Clinical And Laboratory Standards Institute [clsi]

Document History
We have no document history for this standard.
Included in Packages
This standard is not included in any packages.
Amendments & Corrections
We have no amendments or corrections for this standard.

As the voice of the U.S. standards and conformity assessment system, the American National Standards Institute (ANSI) empowers its members and constituents to strengthen the U.S. marketplace position in the global economy while helping to assure the safety and health of consumers and the protection of the environment.